ABCB1 and cytochrome P450 polymorphisms: Clinical pharmacogenetics of clozapine

Journal of Clinical Psychopharmacology

Volumn 29, Issue 4, 2009, Pages 319-326

  Jaquenoud Sirot, Eveline ^a   Knezevic, Branka ^a   Morena, Gina Perla ^b   Harenberg, Sabine ^a   Oneda, Beatrice ^b   Crettol, Séverine ^b   Ansermot, Nicolas ^b   Baumann, Pierre ^b   Eap, Chin B ^b,c  

^a Psychiatrische Dienste Aargau AG   (Switzerland)

^b Hopital de Cery   (Switzerland)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

ABCB1; Clozapine; CYP1A2; CYP2C19; CYP3A4; Plasma concentration

Indexed keywords

AROMATASE; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; FLUVOXAMINE; MIDAZOLAM; MULTIDRUG RESISTANCE PROTEIN 1; NORCLOZAPINE;

ADULT; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG BLOOD LEVEL; ENVIRONMENTAL FACTOR; FEMALE; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MONOTHERAPY; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; SMOKING HABIT; STEADY STATE; WEIGHT GAIN;

ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; CAFFEINE; CLOZAPINE; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FEMALE; FLUVOXAMINE; GENOTYPE; HUMANS; MALE; MIDAZOLAM; MIDDLE AGED; P-GLYCOPROTEIN; PHENOTYPE; POLYMORPHISM, GENETIC; SUBSTRATE SPECIFICITY; SWITZERLAND; YOUNG ADULT;

EID: 68449088877     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181acc372     Document Type: Article

References (50)

1. Wahlbeck K, Cheine M, Essali A, et al. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry. 1999;156:990-999.
2. Buckley P, Miller A, Olsen J, et al. When symptoms persist: clozapine augmentation strategies. Schizophr Bull. 2001;27:615-628.
3. Perry PJ, Miller DD, Arndt SV, et al. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry. 1991;148:231-235.
4. Spina E, Avenoso A, Facciola G, et al. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology. 2000;148:83-89.
5. Freeman DJ, Oyewumi LK. Will routine therapeutic drug monitoring have a place in clozapine therapy? Clin Pharmacokinet. 1997;32:93-100.
6. Bender S, Eap CB. Very high cytochrome P4501A2 activity and nonresponse to clozapine. Arch Gen Psychiatry. 1998;55:1048-1050.
7. Fang J, Gorrod JW Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs. Cell Mol Neurobiol. 1999;19:491-510.
8. Özdemir V, Kalow W, Posner P, et al. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentration in patients with schizophrenia. J Clin Psychopharmacol. 2001;21:398-407.
9. Olesen Oy Linnet K. Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J Clin Pharmacol. 2001;41:823-832.
10. Meyer JM. Individual changes in clozapine levels after smoking cessation: results and a predictive model. J Clin Psychopharmacol. 2001;21:569-574.
11. Jerling M, Lindström L, Bondesson U, et al. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit. 1994;16:368-374.
12. Dahl ML, Llerena A, Bondesson U, et al. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. Br J Clin Pharmacol. 1994;37:71-74.
13. Boulton DW, DeVane CL, Liston HL, et al. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002;71:163-169.
14. Maines LW, Antonetti DA, Wolpert EB, et al. Evaluation of the role of P-glycoprotein in the uptake of paroxetine, clozapine, phenytoin and carbamazepine by bovine retinal endothelial cells. Neuropharmacology. 2005;49:610-617.
15. Marzolini C, Paus E, Buclin T, et al. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004;75:13-33.
16. Eap CB, Buclin T, Cucchia G, et al. Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. Eur J Clin Pharmacol. 2004;60:237-246.
17. Lu ML, Lane HY, Lin SK, et al. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry. 2004;65:766-771.
18. de Leon J, Diaz FJ, Josiassen RC, et al. Weight gain during a double-blind multidosage clozapine study. J Clin Psychopharmacol. 2001;21:22-21.
19. Fuhr U, Rost KL. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics. 1994;4:109-116.
20. Eap CB, Bender S, Jaquenoud Sirot E, et al. Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J Clin Psychopharmacol. 2004;24:214-219.
21. Eap CB, Gaillard N, Powell K, et al. Simultaneous determination of plasma levels of fluvoxamine and of the enantiomers of fluoxetine and norfluoxetine by gas chromatography-mass spectrometry. J Chromatogr B Biomed Appl. 1996;682:265-272.
22. Eap CB, Bouchoux G, Powell GK, et al. Determination of picogram levels of midazolam, and 1- and 4-hydroxymidazolam in human plasma by gas chromatography-negative chemical ionization-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;802:339-345.
23. Crettol S, Deglon JJ, Besson J, et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther. 2006;80:668-681.
24. Crettol S, Venetz JP, Fontana M, et al. CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients. Ther Drug Monit. 2008;30:689-699.
25. Christensen M, Tybring G, Mihara K, et al. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther. 2002;71:141-152.
26. Kashuba AD, Nafziger AN, Kearns GL, et al. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clin Pharmacol Ther. 1998;64:257-268.
27. Pinninti NR, de Leon J. Interaction of sertraline with clozapine. J Clin Psychopharmacol. 1997;17:119-120.
28. Spina E, Avenoso A, Salemi M, et al. Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline. Pharmacopsychiatry. 2000;33:213-217.
29. Spina E, Avenoso A, Facciola G, et al. Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. Int Clin Psychopharmacol. 1998;13:141-145.
30. Bugamelli F, Mandrioli R, Kenndler E, et al. Possible levomepromazine-clozapine interaction: two case reports. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:567-570.
31. Miller DD. Effect of phenytoin on plasma clozapine concentrations in two patients. J Clin Psychiatry. 1991;52:23-25.
32. Frick A, Kopitz J, Bergemann N. Omeprazole reduces clozapine plasma concentrations. A case report. Pharmacopsychiatry. 2003;36:121-123.
33. Jaquenoud Sirot E, van der Velden J, Rentsch K, et al. Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance. Drug Saf 2006;29:735-768.
34. Solus JF, Arietta BJ, Harris JR, et al. Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics. 2004;5:895-931.
35. Bertilsson L, Carrillo JA, Dahl ML, et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol. 1994;38:471-473.
36. Eiermann B, Engel G, Johansson I, et al. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol. 1997;44:439-446.
37. Sachse C, Brockmoller J, Bauer S, et al. Functional significance of a C->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol. 1999;47:445-449.
38. Kootstra-Ros JE, Smallegoor W, Van Der WJ. The cytochrome P450 CYP1A2 genetic polymorphisms *1F and *1D do not affect clozapine clearance in a group of schizophrenic patients. Ann Clin Biochem. 2005;42:216-219.
39. Van der Weide J, Steijns LS, van Weelden MI The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics. 2003;13:169-172.
40. Haslemo T, Eikeseth PH, Tanum L, et al. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol. 2006;62:1049-1053.
41. Rostami-Hodjegan A, Amin AM, Spencer EP, et al. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol. 2004;24:70-78.
42. Diaz FJ, Santoro V, Spina E, et al. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry. 2008;41:81-91.
43. Bondolfi G, Morel F, Crettol S, et al. Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Ther Drug Monit. 2005;27:539-543.
44. Lammers CH, Deuschle M, Weigmann H, et al. Coadministration of clozapine and fluvoxamine in psychotic patients-clinical experience. Pharmacopsychiatry. 1999;32:76-77.
45. Knezevic B, Ramseier F, Jaquenoud Sirot E. Clozapine-fluvoxamine combination therapy: how much fluvoxamine? Results from a case series. Eur Psychiatry. 2006;21:S225.
46. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37:243-265.
47. Carrillo JA, Herraiz AG, Ramos SI, et al. Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. J Clin Psychopharmacol. 1998;18:311-316.
48. Lane HY, Chiu CC, Kazmi Y. Lack of CYP3A4 inhibition by grapefruit juice and ketoconazole upon clozapine administration in vivo. Drug Metabol Drug Interact. 2001;18:263-278.
49. Ohlsson RS, Mwinyi J, Andersson M, et al. Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects. Eur J Clin Pharmacol. 2008;64:1175-1179.
50. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19:1-93.